SEC Filing Summary: AspenBio Pharma, Inc. (Form 8-K)
Business Context and Reporting Period
This Form 8-K was filed by AspenBio Pharma, Inc. on August 8, 2012. The report serves as a current disclosure pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. The registrant is incorporated in Colorado with principal executive offices in Castle Rock, CO.
Note: The request metadata referenced "Riot Platforms, Inc.", but the provided filing text explicitly identifies the registrant as "AspenBio Pharma, Inc." This summary reflects the content of the provided text.
Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This document is a procedural filing to announce a press release rather than a financial statement.
Material Changes
No material financial changes or operational updates are detailed within the body of this Form 8-K. The filing solely references the issuance of a press release titled "AspenBio Pharma to Provide Shareholders with Business Update."
Guidance, Outlook, and Management Commentary
- Regulation FD Disclosure (Item 7.01): The Company issued a press release on August 8, 2012, to provide shareholders with a business update.
- Exhibits (Item 9.01): The full text of the press release is attached as Exhibit 99.1. The filing itself contains no specific guidance, risk factors, or management commentary beyond the announcement of the update.
Key Facts for Investor Verification
- Verify the content of the attached press release (Exhibit 99.1) for the actual business update details, as the 8-K body contains no substantive data.
- Confirm the registrant identity is AspenBio Pharma, Inc., not Riot Platforms, Inc.
- Note that no financial figures are disclosed in this specific filing.